Indigenous CAR-T Therapy Signals New Phase for India's Cancer Care and Biotech Manufacturing
Feb 19, 2026
New Delhi [India], February 19: When Ms. Arora's cancer returned, the emotional weight of relapse was immediate. Having already undergone standard lines of treatment for non-Hodgkin's lymphoma (NHL) after her diagnosis in 2022, she now faced a narrower set of options--each complex, each uncertain. "I remember feeling that the ground had shifted again," she says. "But my medical team walked me through the available options, and we decided to move forward with an indigenous CAR-T therapy." Today, her story forms part of a broader shift unfolding in India's oncology ecosystem--one marked not just by clinical innovation, but by homegrown scientific capability.
Read More...
